Ionis reports FY2022 revenue $587M, net loss $270M; eplontersen NDA submitted; 2023 guidance revenue >$575M

IONIS PHARMACEUTICALS INC

2022-FY EPS reported -$1.90 revenue$151,890,000

FY2022 total revenue $587M (down from $810M in 2021); net loss $270M vs $29M loss in 2021.
Q4 2022 revenue $152M, net loss $52M; non-GAAP net loss $168M.
Eplontersen NDA submitted to FDA for ATTRv-PN; tofersen under FDA/EMA review; olezarsen Fast Track for FCS.
2023 guidance: revenue >$575M, non-GAAP operating expenses ~$970-995M, net operating loss <$425M.
Cash, cash equivalents and short-term investments $2.0B at Dec 31, 2022; plus $500M from Royalty Pharma in Jan 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IONIS PHARMACEUTICALS INC reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 22, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-007944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.